U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07118436) titled 'Liquid Biopsy Under PSMA Radioligand Therapy' on July 28.
Brief Summary: Prostate cancer is the second most common cause of cancer death in men worldwide. After exhausting guideline-compliant therapies or in accordance with the approval of 177Lu-PSMA-617 (Pluvicto(R)), patients with metastatic castration-resistant prostate cancer (mCRPC) can be offered radioligand therapy (RLT) that targets the prostate-specific membrane antigen (PSMA). Despite an initially high response rate to PSMA-RLT, the disease often progresses rapidly again. The underlying mechanisms are still poorly understood.
Liquid biopsy (LBx) involves the collection an...